Halozyme Therapeutics (HALO) Falls Short of Q4 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.34 +1.34%
Revenue Growth %: +37.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: +37.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reported Q4 loss of $0.17, $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme Therapeutics (HALO) PT Raised to $79 at JPMorgan
- Socket Mobile (SCKT) Reports Q3 Loss of $0.09
- HCI Group (HCI) Tops Q3 EPS by 245c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
